Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Mulu, Andargachew ^a,b   Maier, Melanie ^a   Liebert, Uwe Gerd ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF GONDAR   (Ethiopia)

Author keywords

Drug resistance; Ethiopia; HIV 1 subtype C; Integrase; Integrase inhibitors; Polymorphism mutations

Indexed keywords

INTEGRASE INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CODON; ENZYME POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MALE; MIDDLE AGED; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; YOUNG ADULT; ANTIVIRAL RESISTANCE; BLOOD; CD4+ T LYMPHOCYTE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUTATION;

CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; RNA, VIRAL;

EID: 84948973600     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0734-3     Document Type: Article

References (32)

1. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, et al. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol. 2009;385:693-713.
2. Engelman A, Krishnan L. Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem. 2012;287:40858-66. doi: 10.1074/jbc.R112.397760.
3. Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem Sci. 2006;31:98-105.
4. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem. 2004;4:965-77.
5. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem. 2000;276:23213-6.
6. Van Maele B, Debyser Z. HIV-1 integration: an-interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev. 2005;7:26-43.
7. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-65.
8. Buzón MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, et al. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir Ther. 2008;13:881-93.
9. Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, et al. High frequency of integrase Q148R minority variants in HIV-infected patient's naive of integrase inhibitors. AIDS. 2010;24:867-73.
10. Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol. 2009;83:10245-9.
11. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, et al. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010;24:2171-9.
12. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retrovir. 2010;26:489-93. doi: 10.1089/aid.2009.0249.
13. Papathanasopoulos MA, Vardas E, Wallis C, Glashoff R, Buttó S, Poli G, et al. Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS vaccine integrated project (AVIP) study. AIDS Res Hum Retrovir. 2010;26:705-9. doi: 10.1089/aid.2009.0281.
14. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-34.
15. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
16. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:480-4.
17. Koyalta D, Charpentier C, Beassamda J, Rey E, Si-Mohamed A, Djemadji-Oudjeil N, et al. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis. 2009;49:155-9.
18. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in Kwa Zulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-97.
19. Mulu, Lange T, Liebert UG, Maier M. Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia. BMC Infect Dis. 2014;. doi: 10.1186/1471-2334-14-158.
20. Huruy K, Maier M, Mulu A, Liebert UG. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia. J Med Virol. 2015;87(6):978-84. doi: 10.1002/jmv.24110.
21. Mulu A, Maier M, Liebert UG. Low incidence of HIV-1C acquired drug resistance 10 years after roll-out of antiretroviral therapy in Ethiopia: a prospective cohort study. PLoS One. 2015;10(10):e0141318. doi: 10.1371/journal.pone.0141318.
22. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. Update of the drug resistance mutations in HIV-1: international AIDS society-USA. Top Antivir Med. 2015; 23(4) (Epub ahead of print).
23. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology. 2008;5:7. doi: 10.1186/1742-4690-5-74.
24. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-54.
25. Oliveira MF, Ramalho DB, Abreu CM, Vubil A, Mabunda N, Ismael N, et al. Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors. AIDS Res Hum Retrovir. 2012;28:1788-92. doi: 10.1089/aid.2012.0058.
26. Turriziani O, Montagna C, Falasca F. Analysis of the integrase gene from hiv-1 positive patients living in a rural area of west Cameroon. AIDS Res Hum Retrovir. 2012;28:1729-33. doi: 10.1089/AID.2011.0266.
27. Passaes CB, Guimarães ML, Fernandez SL, Lorete Rdos S, Teixeira SL, Fernandez JC, et al. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr. 2000;51:7-12.
28. Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011;83:751-9.
29. Eshleman SH, Hudelson SE, Smith P, Hackett J, Holzmayer V, Swanson P, et al. Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retrovir. 2009;25:343-5. doi: 10.1089/aid.2008.0236.
30. Abebe A, Pollakis G, Fontanet AL, Fisseha B, Tegbaru B, Kliphuis A, et al. Identification of a genetic subcluster of HIV type 1 subtype C (C') widespread in Ethiopia. AIDS Res Hum Retrovir. 2000;16:1909-14.
31. Pollakis G, Abebe A, Kliphuis A, De Wit TF, Fisseha B, Tegbaru B, et al. Recombination of HIV type 1C (C'/C) in Ethiopia: possible link of EthHIV-1C' to subtype C sequences from the high-prevalence epidemics in India and Southern Africa. AIDS Res Hum Retrovir. 2003;19:999-1008.
32. Soares EA, Santos AF, Sousa TM, Sprinz E, Martinez AM, Silveira J, et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One. 2007;15(28):730.